Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity‐related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization. Current pediatric obesity treatment algorithms for pediatric primary care providers focus primarily on intensive lifestyle intervention with escalation of treatment intensity through four stages of intervention. Although a recent surge in the number of Food and Drug Administration‐approved medications for obesity treatment has emerged in adults, pharmacotherapy options for youth remain limited. Recognizing treatment and knowledge gaps related to pharmacological agents and the urgent need for more effective treatment strategies in this population, discussed here are the efficacy, safety, and clinical application of obesity pharmacotherapy in youth with obesity based on current literature. Legal ramifications, informed consent regulations, and appropriate off‐label use of these medications in pediatrics are included, focusing on prescribing practices and prescriber limits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barlow, S. E., & and the Expert Committee (2007) · Pediatrics · doi:10.1542/peds.2007-2329c · Cited by 4,497
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Prevalence of Obesity and Severe Obesity in US Children, 1999–2016
Skinner, A. C., Ravanbakht, S. N., Skelton, J. A., Perrin, E. M., & Armstrong, S. C. (2018) · Pediatrics · doi:10.1542/peds.2017-3459 · Cited by 1,412 · cited 4×
“We therefore recommend standard informed consent (and assent) documentation within the electronic medical record describing (1) that the conversation about off-label drug use occurred, (2) that the patient/family member(s) understand risks and benefits, (3) the potential major and minor drug side effects reviewed, (4)…”
BackgroundMethodInfluentialPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 1×
“This algorithm is consistent with adult and pediatric guidelines that recommend discontinuation of an obesity medication, at maximum appropriate dose, if less than 5% weight loss/ BMI reduction from baseline is achieved within 12 weeks (60-62).”
MethodSelf-citationBody-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood
Twig, G., Yaniv, G., Levine, H., Leiba, A., Goldberger, N., Derazne, E., Ben-Ami Shor, D., Tzur, D., Afek, A., Shamiss, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1503840 · Cited by 1,003 · cited 4×
“We therefore recommend standard informed consent (and assent) documentation within the electronic medical record describing (1) that the conversation about off-label drug use occurred, (2) that the patient/family member(s) understand risks and benefits, (3) the potential major and minor drug side effects reviewed, (4)…”
BackgroundMethodInfluentialKelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980 · cited 1×
“…(without pharmacotherapy) can result in clinically meaningful weight loss in the short term in younger children ( 10-12 years), but older youth tend to respond less favorably to lifestyle intervention and have higher onset of disease progression with the development of comorbidities (15,16,19,53).”
BackgroundSelf-citationRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Weight loss and health status 3 years after bariatric surgery in adolescents
Inge, T. H., Courcoulas, A. P., Jenkins, T. M., Michalsky, M. P., Helmrath, M. A., Brandt, M. L., Harmon, C. M., Zeller, M. H., Chen, M. K., Xanthakos, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506699 · Cited by 750 · cited 3×
“A randomized, placebo-controlled, double-blind study to assess safety, tolerability, and pharmacokinetics of liraglutide 3.0 mg in adolescents (12-17 years of age; Tanner staging 2-5; n = 21; BMI ≥ 95th percentile for age and sex [30 ≤ BMI ≤ 45]) was recently completed (101).”
BackgroundMethodInfluentialSelf-citationOff-label prescribing among office-based physicians
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1021 · Cited by 711 · cited 1×
“Off-label drug use is especially common in pediatrics, a population for which conducting clinical trials might be challenging (64-69).”
BackgroundChanoine, J.-P., Hampl, S., Jensen, C., Boldrin, M., & Hauptman, J. (2005) · JAMA · doi:10.1001/jama.293.23.2873 · Cited by 624
Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA · doi:10.1001/jama.2014.15298 · Cited by 601
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L. L., Mai, K., Blume-Peytavi, U., Grüters, A., & Krude, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512693 · Cited by 485 · cited 2×
“5 kg after 12 weeks in patient 2) (118).”
BackgroundFlegal, K. M., Wei, R., Ogden, C. L., Freedman, D. S., Johnson, C. L., & Curtin, L. R. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28335 · Cited by 435
Ten common questions (and their answers) about off-label drug use
Wittich, C. M., Burkle, C. M., & Lanier, W. L. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.04.017 · Cited by 368 · cited 1×
“…date, court systems have not mandated a formal informed consent process for off-label drug use due to concerns about impingement of direct patient care and impediments to communications along with unnecessary concerns or alarms elicited to the individual patient and/or family members involved (65).”
BackgroundInge, T. H., Jenkins, T. M., Xanthakos, S. A., Dixon, J. B., Daniels, S. R., Zeller, M. H., & Helmrath, M. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30315-1 · Cited by 298
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274 · cited 1×
“This is comparable to an adult study that found −5.1% weight loss at 28 weeks with phentermine 15 mg once-daily monotherapy (74).”
ResultInfluentialCardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265 · cited 1×
“No adverse cardiovascular safety signals have thus far emerged with lorcaserin from the large cardiovascular safety trial (108).”
BackgroundRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2006) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd002967.pub2 · Cited by 163
Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1232 · Cited by 123
Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis
Al Khalifah, R. A., Florez, I. D., Dennis, B., Thabane, L., & Bassilious, E. (2016) · PEDIATRICS · doi:10.1542/peds.2015-4089 · Cited by 91
Björkhem-Bergman, L., Asplund, A. B., & Lindh, J. D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109353461 · Cited by 72
Nathan, B. M., Rudser, K. D., Abuzzahab, M. J., Fox, C. K., Coombes, B. J., Bomberg, E. M., & Kelly, A. S. (2016) · Clinical Obesity · doi:10.1111/cob.12128 · Cited by 39 · cited 1×
“In adolescent trials, compliance with the injection regimen was excellent (≥ 94%), and exenatide was generally well tolerated (the most common adverse event was mild nausea in 36%, followed by vomiting, head-ache, abdominal pain, and diarrhea) (93-95).”
BackgroundSelf-citation
Cited by
Clinical management and treatment of obesity in China
Zeng, Q., Li, N., Pan, X.-F., Chen, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00047-4 · Cited by 269
Phentermine/Topiramate for the Treatment of Adolescent Obesity
Kelly, A. S., Bensignor, M. O., Hsia, D. S., Shoemaker, A. H., Shih, W., Peterson, C., & Varghese, S. T. (2022) · NEJM Evidence · doi:10.1056/evidoa2200014 · Cited by 169
Self-citationKleinendorst, L., Abawi, O., van der Voorn, B., Jongejan, M. H. T. M., Brandsma, A. E., Visser, J. A., van Rossum, E. F. C., van der Zwaag, B., Alders, M., Boon, E. M. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232990 · Cited by 62
“[51] These GLP-1 agonists might also be a future treatment option for patients with genetic obesity disorders, as they have been shown to be equally as effective in adults with heterozygous MC4Rmutations compared to adults without.”
BackgroundCost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents
Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Woo Baidal, J. A., Kelly, A. S., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29178 · Cited by 42
Self-citationVosburg, R. W., El Chaar, M., El Djouzi, S., Docimo, S., Choi, D., LaMasters, T., Srivastava, G., Shukla, A. P., Oviedo, R. J., Fitch, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.07.002 · Cited by 24
Self-citation
Metadata
- Authors
- Srivastava, G., Fox, C. K., Kelly, A. S., Jastreboff, A. M., Browne, A. F., Browne, N. T., Pratt, J. S. A., Bolling, C., Michalsky, M. P., Cook, S., Lenders, C. M., & Apovian, C. M.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2019-01-24
- Volume
- 27
- Issue
- 2
- Pages
- 190-204
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2913951823
- Cited by
- 130
- References
- 22
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.